Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 8/20 | 0.47 |
| ▸ | JAK2 | O60674 | 7/20 | 0.47 |
| ▸ | JAK1 | P23458 | 5/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634092 | 0.89 | PAK1 (0.48) | PAK1JAK2JAK1EPHB4IRAK4 | |
| SCHEMBL2463301 | 0.82 | JAK2 (0.42) | PAK1JAK2JAK1JAK3 | |
| SCHEMBL2464911 | 0.81 | CDK2 (0.40) | JAK2SYK | |
| SCHEMBL14633531 | 0.81 | CDK2 (0.44) | JAK1EPHB4JAK3SYK | |
| SCHEMBL2513775 | 0.80 | EPHB4 (0.56) | PAK1JAK2JAK1EPHB4JAK3 | |
| SCHEMBL2472742 | 0.75 | JAK2 (0.40) | PAK1JAK2JAK1IRAK4JAK3 | |
| Trifluoroacetic Acid SCHEMBL14634036 | 0.75 | EPHB4 (0.51) | PAK1JAK2JAK1EPHB4JAK3 | |
| SCHEMBL14634292 | 0.73 | RIPK2 (0.44) | EPHB4 | |
| SCHEMBL2434666 | 0.72 | PTGS2 (0.38) | JAK2JAK1JAK3SYK | |
| SCHEMBL14634260 | 0.72 | JAK2 (0.45) | PAK1JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | PAK1 287/4885JAK2 45/4885JAK1 58/4885 |
| US-20130023534-A1 | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | CDK2, MAP3K19, MAP3K1 | PAK1 118/4885JAK2 98/4885JAK1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.